サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1138312

がん幹細胞の世界市場-2022-2029

Global Cancer Stem Cells Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
がん幹細胞の世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

世界のがん幹細胞市場に影響を与える要因は、幹細胞研究およびがんに対する資金調達の増加と、抗CSCs治療薬のパイプラインの増加です。

幹細胞研究およびがん研究への資金提供の増加は、市場成長の原動力となることが期待されます。

国立がん研究所（NCI）は、がん研究に対する世界最大の資金提供者です。同研究所の年間予算は、議会が定めた通り、およそ62億5,000万米ドルです。これらの助成金は、NCIをはじめ、世界中のがんセンター、病院、地域診療所、大学などでがん研究を継続するためのインフラ整備に役立てられています。

国立がん研究所（NCI）には、研究を行う、あるいは研究プロジェクトを管理する様々な部門やセンターがあります。NCIの2020年度の資金は64億米ドル（CURES Actの資金1億9500万米ドルを含む）で、前年度から9.2％、5億2400万米ドル増加しました。米国がん研究協会（AACR）は、がんを過去のものにすることを目的とした世界初かつ最大のがん研究機関です。さらに、CIRMは、国立衛生研究所以外の幹細胞研究に対する最大の資金源として、アンメットメディカルニーズを持つ患者さんに医薬品を迅速に届けることに焦点を当てた革新的な研究イニシアティブを後援しています。これには、探索研究、トランスレーショナルリサーチなどの基礎研究から臨床試験までが含まれます。したがって、がん研究と幹細胞への資金提供の増加は、予測期間中の市場成長を促進すると予想されます。

高コストが予測期間中の市場成長の妨げになることが予想されます。

細胞治療やその他の再生医療は、現代医療に変革をもたらす可能性のある貢献として支持を集めていますが、その分、高額な費用がかかります。人口の増加と高齢化はすでに公的医療費を圧迫しており、多くの民間保険会社の予算も圧迫しています。しかし、支払者のキャッシュフロー・マネジメント・システムは、そのような状況にはありません。

業界分析

がん幹細胞市場は、ポーターファイブフォース、サプライチェーン、価格分析など、様々な業界要因に基づく市場の詳細な分析を提供しています。

COVID-19影響度分析

COVID-19に対する幹細胞治療の利用は、市場成長にプラスの影響を与えると予想されます。例えば、抗ウイルス剤、抗マラリア剤、抗炎症剤などは、現在COVID-19疾患の治療法として研究されている治療法の一つです。これらの治療法は患者の回復と長生きを助けますが、この病気によって引き起こされた肺の損傷を完全に回復させることはできません。幹細胞治療、さらに最近では、幹細胞が放出する細胞外小胞（EV）が、COVID-19による肺の損傷を修復しながら炎症を抑える可能性のある、新規で有望な治療法として注目されています。

幹細胞は、そのEVを介して免疫調節作用、抗酸化作用、修復作用などの治療効果を発揮すると推定され、単独または他の治療薬との併用でCOVID-19患者に有用である可能性があります。現在、COVID-19の治療薬としてMSCを検討している臨床試験は17件あるが、そのほとんどが静脈内投与で、MSC由来のエクソソームを吸入して試験している実験は1件のみです。したがって、幹細胞治療への需要が市場成長を促進すると予想されます。

世界のがん幹細胞市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 幹細胞研究およびがん研究への資金提供の増加が市場成長を促進すると予想されます。
    • 抑制要因
      • 高コストが予測期間中の市場成長を阻害すると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • アンメットニーズ
  • サプライチェーン
  • プライシング分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19発売前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 がんの種類別

  • 血液がん
  • 乳がん
  • 大腸がん
  • 肺がん
  • 肝臓がん
  • 脳腫瘍
  • その他

第8章 作用機序別

  • 幹細胞を用いたがん治療
    • 自家幹細胞移植
    • 同種幹細胞移植
  • がん幹細胞（CSC）を標的とした治療法
    • 抗がん性幹細胞治療薬別
      • パスウェイインヒビター
      • WNTシグナル伝達経路
      • ヘッジホッグシグナル伝達経路
      • ノッチシグナル伝達経路
      • その他
      • 表面マーカーベース
      • 免疫回避・腫瘍微小環境標的療法
      • ナノ粒子を用いた治療法
      • その他
    • 製品別
      • 細胞培養
      • 細胞分離
      • 細胞解析
      • 分子生物学的解析
      • その他

第9章 エンドユーザー別

  • がん専門治療施設
  • 病院
  • 研究機関
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク

第12章 企業プロファイル

  • Merck KGaA
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Bionomics.
  • AbbVie, Inc.
  • Stemline Therapeutics, Inc
  • LONZA
  • PromoCell GmbH
  • Miltenyi Biotec
  • STEMCELL Technologies Inc
  • BIOTIME, Inc

第13章 世界のがん幹細胞市場-DataM

目次
Product Code: DMPH372

Market Overview

Cancer stem cells market size is estimated to reach USD million by 2029, growing at a CAGR of 6.7 % during the forecast period (2022-2029).

Cancer stem cells are uncommon immortal cells seen in tumors that give rise to a diverse range of cell types that make up the tumor. These cells have been found in a number of human malignancies and may be employed as cancer therapeutic targets.

Market Dynamics

The factors influencing the global cancer stem cells market are increasing funding for stem cell research and cancer and the growing anti-CSCs therapeutics pipeline.

Increasing funding for stem cell research and cancer research is expected to drive market growth.

The National Cancer Institute (NCI) is the world's largest funder of cancer research. The institute's annual budget is roughly $6.25 billion, as established by Congress. These grants help finance the infrastructure that allows cancer research to continue at NCI and other cancer centers, hospitals, community clinics, and colleges worldwide.

The National Cancer Institute (NCI) contains a variety of divisions and centers that perform research or manage research projects. The NCI had $6.4 billion in funds in FY 2020 (including $195 million in CURES Act funding), up 9.2 percent or $524 million from the previous fiscal year. The American Association for Cancer Research (AACR) is the world's first and biggest cancer research organization dedicated to making cancer a thing of the past. Moreover, CIRM sponsors innovative research initiatives focused on expediting medicines to patients with unmet medical needs as the largest source of financing for stem cell research outside the National Institutes of Health. This includes everything from basic research, such as discovery and translational research, to clinical trials. Hence, the increased funding for cancer research and stem cells is expected to drive market growth in the forecast period.

High costs are expected to hamper the market's growth in the forecast period.

Cellular treatments and other regenerative medicines are gaining traction as potentially transformational contributions to modern medicine but at a hefty price tag. Growing and aging populations are already straining public healthcare costs, and many commercial insurers' budgets are also being pressured. Most payers' cash-flow management systems are not.

Industry Analysis

The cancer stem cells market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis etc.

COVID-19 Impact Analysis

The use of stem cell therapies for COVID-19 is expected to positively impact market growth. For instance, antiviral, antimalarial, and anti-inflammatory drugs are among the treatments now being studied for the treatment of COVID-19 disease. While these treatments can help patients recover and live longer, they do not completely restore the lung damage caused by this disease. Stem cell therapies, and more recently, their released extracellular vesicles (EVs), are emerging as novel and promising treatments that may reduce inflammation while also repairing COVID-19-induced lung damage.

Stem cells presumably exert their immunomodulatory, anti-oxidant, and reparative therapeutic actions through their EVs, which could be useful in people with COVID-19, either alone or combined with other treatment drugs. There are currently 17 clinical trials examining MSCs for the treatment of COVID-19, most of which are administered intravenously, with just one experiment testing MSC-derived exosomes by inhalation. Hence, the demand for stem cell therapies is expected to drive market growth.

Segment Analysis

Stem Cell-based Cancer Therapy segment is expected to hold the largest market share in cancer stem cells market.

The stem cell-based cancer therapy segment accounted for the largest market share in 2021. Stem cell-based cancer therapy is further segmented into autologous SC transplants and allogeneic transplants. Stem cell transplants are treatments that help people who have had their blood-forming stem cells destroyed by heavy doses of chemotherapy or radiation therapy used to treat certain cancers. Blood-forming stem cells are crucial because they differentiate into many types of blood cells. An autologous stem cell transplant replaces diseased or damaged bone marrow with healthy blood stem cells from the recipient's body. An autologous bone marrow transplant is similar to an autologous stem cell transplant. When compared to stem cells from a donor, using cells from one's own body during a stem cell transplant has some advantages. If the body produces enough healthy bone marrow cells, an autologous stem cell transplant may be an option.

These cells can be collected, frozen, and used later. People who require severe doses of chemotherapy and radiation to cure their conditions frequently have autologous stem cell transplants. The bone marrow is likely to be damaged due to these treatments. The damaged bone marrow can be replaced with an autologous stem cell transplant. In contrast, an allogeneic stem cell transplant replaces bone marrow that isn't producing enough healthy blood cells with healthy blood stem cells from a donor. An allogeneic bone marrow transplant is similar to an allogeneic stem cell transplant.

Geographical Analysis

North American region holds the largest market share in the global cancer stem cells market

The growing prevalence of cancer and increasing R&D is expected to drive the market in this region. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed, and there will be 608,570 cancer deaths in the United States. In contrast, in 2022, roughly 1.9 million people will be diagnosed with cancer in the United States. An estimated 287,850 women and 2,710 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. Prostate cancer is the leading cancer diagnosis among men and the second most common overall, with 268,490 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis, with an estimated 236,740 new cases.

Moreover, although stem cell research is allowed in the United States, it is subject to funding and usage restrictions. Blood cell-forming adult stem cells found in the bone marrow are currently the only stem cells employed to treat illness. Furthermore, many companies in this region are key players, such as Thermo Fisher Scientific, AbbVie, Inc., Stemline Therapeutics, Inc, STEMCELL Technologies, Inc, and others. In addition, Gamida-Cell Ltd., a U.S.-based next-generation stem cell therapy research and development business, will begin rolling out Biologics License Application (BLA) submissions for omidubicel on January 31, 2022. Omidubicel is a bone marrow stem cell transplant clinically developed for patients with blood malignancies. Gamida-Cell Ltd. stated that the rolling submission was approved following good comments from the type B meeting with the FDA.

Competitive Landscape

Major key players in the cancer stem cells market are Merck KGaA, Thermo Fisher Scientific, Inc., Bionomics, AbbVie, Inc., Stemline Therapeutics, Inc, LONZA, PromoCell GmbH, Miltenyi Biotec, STEMCELL Technologies Inc., BIOTIME, Inc.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and based in Waltham, Massachusetts. The company offers worldwide life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

Thermo Fisher Scientific provides optimized solutions for cancer stem cell research-from identification and culturing to genomic and functional analysis.

  • Attune NxT Flow Cytometer
  • Cell Health Assays
  • TaqMan Protein Expression Assay

The global cancer stem cells market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing funding for stem cell research and cancer research is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs are expected to hamper the market's growth in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type Segment
  • 7.2. Blood Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Liver Cancer
  • 7.7. Brain Cancer
  • 7.8. Others

8. By Mode of Action

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 8.1.2. Market Attractiveness Index, By Mode of Action Segment
  • 8.2. Stem Cell-based Cancer Therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Autologous Stem Cell Transplant
    • 8.2.4. Allogeneic Stem Cell Transplant
  • 8.3. Targeted Cancerous Stem Cells (CSCs)
    • 8.3.1. By Anti-Cancer Stem Cell Therapeutics
      • 8.3.1.1. Pathway Inhibitors
      • 8.3.1.1.1. WNT Signaling Pathway
      • 8.3.1.1.2. Hedgehog Signaling Pathway
      • 8.3.1.1.3. Notch Signaling Pathway
      • 8.3.1.1.4. Others
      • 8.3.1.2. Surface Marker-based
      • 8.3.1.3. Immuno-evasion & Targeting Tumor Microenvironment
      • 8.3.1.4. Nanoparticle-based Therapies
      • 8.3.1.5. Others
    • 8.3.2. By Products
      • 8.3.2.1. Cell Culturing
      • 8.3.2.2. Cell Separation
      • 8.3.2.3. Cell Analysis
      • 8.3.2.4. Molecular Analysis
      • 8.3.2.5. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Specialised Cancer Treatment Centers*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Hospitals
  • 9.4. Research Institutes
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Merck KGaA*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. Thermo Fisher Scientific, Inc.
  • 12.4. Bionomics.
  • 12.5. AbbVie, Inc.
  • 12.6. Stemline Therapeutics, Inc
  • 12.7. LONZA
  • 12.8. PromoCell GmbH
  • 12.9. Miltenyi Biotec
  • 12.10. STEMCELL Technologies Inc
  • 12.11. BIOTIME, Inc

LIST NOT EXHAUSTIVE

13. Global Cancer Stem Cells Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us